Subgroup analysis revealed the most significant PFS benefit in ALK‐positive ALCL, followed by ALK‐negative ALCL, whereas the benefit was more limited in PTCL‐NOS and angioimmunoblastic T‐cell lymphoma (AITL). This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.